NCT05779007View on ClinicalTrials.gov

Dose Reduction and Discontinuation With Anti-Fibrotic Medications

CompletedOBSERVATIONAL
Enrollment

2,778

Participants

Timeline

Start Date

April 18, 2023

Primary Completion Date

July 14, 2023

Study Completion Date

July 14, 2023

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

Pirfenidone

Pirfenidone

DRUG

Nintedanib

Nintedanib

Trial Locations (1)

06877

Boehringer Ingelheim, Ridgefield

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT05779007 - Dose Reduction and Discontinuation With Anti-Fibrotic Medications | Biotech Hunter | Biotech Hunter